Charles River (CRL) Q2 EPS Jumps 11%

Charles River Laboratories International (NYSE:CRL), a global provider of laboratory services and research models for drug development, announced its latest earnings results on August 6, 2025. The company reported GAAP revenue of $1,032.1 million, slightly up 0.6% year-over-year (GAAP), and ahead of the estimated $985.2 million (GAAP). Non-GAAP earnings per share (EPS) came in at $3.12, beating the analyst expectation of $2.50 (non-GAAP) and climbing 11.4% year over year on a non-GAAP basis. Although non-GAAP operating margins improved, GAAP profit and margins dropped due to higher charges relating to amortization, restructuring, and legal fees. The quarter reflected cost control and segment margin gains, but underlying organic sales trended negative, particularly in its largest business line. Management raised full-year 2025 guidance based on the performance but noted persistent operational challenges. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Charles River Laboratories International is a leading provider of research models, laboratory services, and manufacturing support for global drug development. Its business helps pharmaceutical and biotechnology companies, government agencies, and academic institutions advance therapies from discovery to safe use in humans. The company operates three primary segments: Discovery & Safety Assessment (DSA), which supports preclinical drug research and safety testing; Research Models & Services (RMS), offering laboratory animal models and related services; and Manufacturing Solutions (MS), focused on drug quality assurance, microbial testing, and contract manufacturing.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool